As arguably the most technologically advanced sport in the world, where cutting-edge R&D is critical to achieving results on the track, it would be reasonable to assume that patents play a pivotal role in protecting...more
The “unwilling licensee” issue has been a vexed one, with uncertainty as to whether such a concept exists, its relevance, and what an implementer must do to avoid becoming one. As for the concept of FRAND itself, there is no...more
The Court of Appeal (Birss LJ, Floyd LJ and Phillips LJ) handed down its judgment in Fibrogen v Akebia on 24 August 2021, overturning Arnold LJ (another Court of Appeal judge) on his judgment on insufficiency when sitting at...more
With the passing by the Privy Council on 8 February 2018 of the Unified Patent Court (Privileges and Immunities) Order 2018 the UK has completed all of the necessary legislative steps to enable it to ratify the UPC Agreement....more
On 21 December 2017 the U.S. District Court for the Central District of California released its judgment in TCL Communications v Ericsson setting a Fair, Reasonable, and Non-Discriminatory (FRAND) rate for Ericsson’s Standard...more
Final Unwired Planet v Huawei judgment published -
On 30 November 2017 the High Court of England and Wales handed down two final judgments on confidentiality in Unwired Planet v Huawei: the final version of the substantive...more
Cybersecurity continues to be headline-grabbing news, particularly following recent reports of high-profile cyber attacks on a number of major well-known corporations. Conscious of their fiduciary duties, boardrooms of global...more
8/1/2016
/ Cybersecurity ,
Data Protection ,
Department of Health and Human Services (HHS) ,
Duty of Care ,
EU ,
General Data Protection Regulation (GDPR) ,
Health Insurance Portability and Accountability Act (HIPAA) ,
Information Commissioner's Office (ICO) ,
Life Sciences ,
Popular ,
UK
The vexed question of how to enforce second medical use patents has dominated the headlines in the last half year. The case of Warner-Lambert v Actavis1 in the English High Court highlighted the serious difficulties...more
9/23/2015
/ Actavis Inc. ,
AstraZeneca ,
Claim Construction ,
EU ,
European Court of Justice (ECJ) ,
FRAND ,
Gilead Sciences ,
Hospira ,
Injunctions ,
IP License ,
IP Portfolio ,
Jurisdiction ,
Life Sciences ,
Patent Infringement ,
Patent Litigation ,
Patent Portfolios ,
Patents ,
Pharmaceutical Patents ,
Teva Pharmaceuticals ,
UK ,
UK Patents Act